taurine has been researched along with Fatty Liver, Nonalcoholic in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study employed a rat model to examine the effects of taurine (Tau) on prevention and therapy of non-alcoholic fatty liver disease (NAFLD)." | 8.02 | Taurine Reduces Liver Damage in Non-Alcoholic Fatty Liver Disease Model in Rats by Down-Regulating IL-9 and Tumor Growth Factor TGF-β. ( Chen, XQ; Huang, L; Lan, LC; Liang, G; Lv, ZL; Shan, QW; Tang, Q; Yang, MX; Yao, Z; Zhu, FL, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) has several phases of flow: from simple steatosis, steatohepatitis, and ending with fibrosis and cirrhosis." | 6.75 | [Taurine in the treatment of non-alcoholic fatty liver disease]. ( Elizarova, EP; Nilova, TV; Noskova, KK; Ovsiannikova, ON; Zvenigorodskaia, LA, 2010) |
| "Taurine is a sulfur-containing-β-amino acid that is widely distributed in mammalian tissues." | 5.48 | Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. ( Ito, T; Kawasaki, A; Murakami, S; Ono, A; Takenaga, T, 2018) |
| "The study employed a rat model to examine the effects of taurine (Tau) on prevention and therapy of non-alcoholic fatty liver disease (NAFLD)." | 4.02 | Taurine Reduces Liver Damage in Non-Alcoholic Fatty Liver Disease Model in Rats by Down-Regulating IL-9 and Tumor Growth Factor TGF-β. ( Chen, XQ; Huang, L; Lan, LC; Liang, G; Lv, ZL; Shan, QW; Tang, Q; Yang, MX; Yao, Z; Zhu, FL, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) has several phases of flow: from simple steatosis, steatohepatitis, and ending with fibrosis and cirrhosis." | 2.75 | [Taurine in the treatment of non-alcoholic fatty liver disease]. ( Elizarova, EP; Nilova, TV; Noskova, KK; Ovsiannikova, ON; Zvenigorodskaia, LA, 2010) |
| "The alleviating effect of PCPE on NAFLD was conducted on male C57BL/6J mice fed an HFD for 16 weeks, and this effect associated with gut microbiota dependent was demonstrated by pseudo-germfree mice treated with antibiotics and fecal microbiota transplantation (FMT)." | 1.72 | Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice. ( Ba, Y; Chen, Q; Chen, X; Guo, Q; Hu, X; Li, X; Wang, X; Wu, X; Xiao, M; Xiong, L; Yu, L; Zhao, W; Zhao, Y, 2022) |
| "Taurine is a sulfur-containing-β-amino acid that is widely distributed in mammalian tissues." | 1.48 | Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. ( Ito, T; Kawasaki, A; Murakami, S; Ono, A; Takenaga, T, 2018) |
| "Inflammation is a key contributor to the pathology of nonalcoholic fatty liver disease (NAFLD), including NASH." | 1.48 | Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway. ( Bai, J; Gao, N; Jiang, L; Liu, X; Pei, P; Qi, S; Qiu, T; Sun, X; Wang, Z; Wei, S; Yan, R; Yang, G; Yang, L; Yao, X, 2018) |
| "Taurine treatment alleviated hepatocyte damage and oxidative stress." | 1.46 | Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats. ( Chen, R; Chen, S; Peng, Z; Wan, J; Wu, B; Zhu, W, 2017) |
| "Taurine is an essential amino acid in humans that proved efficacy as a non-pharmacological therapy in a plethora of diseases; however, its impact on NAFLD remains elusive." | 1.46 | A Novel Role of SIRT1/ FGF-21 in Taurine Protection Against Cafeteria Diet-Induced Steatohepatitis in Rats. ( Abd Elwahab, AH; Ramadan, BK; Schaalan, MF; Tolba, AM, 2017) |
| "Non-alcoholic fatty liver disease (NAFLD) is the commonest form of chronic liver disease in developed countries." | 1.40 | Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis. ( Azuma, T; Hoshi, N; Kawano, Y; Minami, A; Nishiumi, S; Terashima, Y; Yoshida, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Yao, Z | 1 |
| Liang, G | 1 |
| Lv, ZL | 1 |
| Lan, LC | 1 |
| Zhu, FL | 1 |
| Tang, Q | 1 |
| Huang, L | 1 |
| Chen, XQ | 1 |
| Yang, MX | 1 |
| Shan, QW | 1 |
| Li, X | 1 |
| Zhao, W | 1 |
| Xiao, M | 1 |
| Yu, L | 1 |
| Chen, Q | 1 |
| Hu, X | 1 |
| Zhao, Y | 1 |
| Xiong, L | 1 |
| Chen, X | 1 |
| Wang, X | 1 |
| Ba, Y | 1 |
| Guo, Q | 1 |
| Wu, X | 1 |
| Yamamoto, S | 1 |
| Sato, I | 1 |
| Fujii, M | 1 |
| Kakimoto, M | 1 |
| Honma, K | 1 |
| Akiyama, N | 1 |
| Sakai, M | 1 |
| Fukuhama, N | 1 |
| Kumazaki, S | 1 |
| Hirohata, S | 1 |
| Kitamori, K | 2 |
| Yamori, Y | 1 |
| Watanabe, S | 1 |
| Zhu, W | 1 |
| Chen, S | 1 |
| Chen, R | 1 |
| Peng, Z | 1 |
| Wan, J | 1 |
| Wu, B | 1 |
| Abd Elwahab, AH | 1 |
| Ramadan, BK | 1 |
| Schaalan, MF | 1 |
| Tolba, AM | 1 |
| Murakami, S | 1 |
| Ono, A | 1 |
| Kawasaki, A | 1 |
| Takenaga, T | 1 |
| Ito, T | 1 |
| Qiu, T | 1 |
| Pei, P | 1 |
| Yao, X | 1 |
| Jiang, L | 1 |
| Wei, S | 1 |
| Wang, Z | 1 |
| Bai, J | 1 |
| Yang, G | 1 |
| Gao, N | 1 |
| Yang, L | 1 |
| Qi, S | 1 |
| Yan, R | 1 |
| Liu, X | 1 |
| Sun, X | 1 |
| Suzuki, Y | 1 |
| Kaneko, R | 1 |
| Nomura, M | 1 |
| Naito, H | 1 |
| Nakajima, T | 1 |
| Ogawa, T | 1 |
| Hattori, H | 1 |
| Seno, H | 1 |
| Ishii, A | 1 |
| Terashima, Y | 1 |
| Nishiumi, S | 1 |
| Minami, A | 1 |
| Kawano, Y | 1 |
| Hoshi, N | 1 |
| Azuma, T | 1 |
| Yoshida, M | 1 |
| Li, M | 1 |
| Reynolds, CM | 1 |
| Sloboda, DM | 1 |
| Gray, C | 1 |
| Vickers, MH | 1 |
| Zvenigorodskaia, LA | 1 |
| Ovsiannikova, ON | 1 |
| Noskova, KK | 1 |
| Nilova, TV | 1 |
| Elizarova, EP | 1 |
| Chang, YY | 1 |
| Chou, CH | 1 |
| Chiu, CH | 1 |
| Yang, KT | 1 |
| Lin, YL | 1 |
| Weng, WL | 1 |
| Chen, YC | 1 |
| Li, H | 1 |
| Wang, L | 1 |
| Yan, X | 1 |
| Liu, Q | 1 |
| Yu, C | 1 |
| Wei, H | 1 |
| Li, Y | 1 |
| Zhang, X | 1 |
| He, F | 1 |
| Jiang, Y | 1 |
| Gentile, CL | 1 |
| Nivala, AM | 1 |
| Gonzales, JC | 1 |
| Pfaffenbach, KT | 1 |
| Wang, D | 1 |
| Wei, Y | 1 |
| Jiang, H | 1 |
| Orlicky, DJ | 1 |
| Petersen, DR | 1 |
| Pagliassotti, MJ | 1 |
| Maclean, KN | 1 |
1 trial available for taurine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
[Taurine in the treatment of non-alcoholic fatty liver disease].
Topics: Adult; Aged; Fatty Liver; Female; Humans; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Diseas | 2010 |
13 other studies available for taurine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Taurine Reduces Liver Damage in Non-Alcoholic Fatty Liver Disease Model in Rats by Down-Regulating IL-9 and Tumor Growth Factor TGF-β.
Topics: Animals; Disease Models, Animal; Down-Regulation; Interleukin-9; Intestinal Mucosa; Liver; Liver Cir | 2021 |
Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
Topics: Animals; Bile Acids and Salts; Gastrointestinal Microbiome; Liver; Male; Mice; Mice, Inbred C57BL; N | 2022 |
Increased Glycine-conjugated and Unconjugated Bile Acid Levels Associated with Aggravation of Nonalcoholic Steatohepatitis and Cardiovascular Disease in SHRSP5/Dmcr Rat.
Topics: Animals; Bile Acids and Salts; Cardiovascular Diseases; Glycine; Non-alcoholic Fatty Liver Disease; | 2023 |
Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats.
Topics: Animals; Antioxidants; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Polyphenols | 2017 |
A Novel Role of SIRT1/ FGF-21 in Taurine Protection Against Cafeteria Diet-Induced Steatohepatitis in Rats.
Topics: Animals; Diet; Fibroblast Growth Factors; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative | 2017 |
Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro.
Topics: Animals; Catalase; Hep G2 Cells; Hepatocytes; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Non-alc | 2018 |
Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway.
Topics: Animals; Arsenic; Autophagy; Cell Survival; Hep G2 Cells; Humans; Inflammation; Mice; Mice, Inbred C | 2018 |
Simple and rapid quantitation of 21 bile acids in rat serum and liver by UPLC-MS-MS: effect of high fat diet on glycine conjugates of rat bile acids.
Topics: Animals; Bile Acids and Salts; Biomarkers; Calibration; Cholesterol, Dietary; Chromatography, Liquid | 2013 |
Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis.
Topics: Animals; Choline; Diet; Fatty Liver; Liver; Liver Cirrhosis; Male; Metabolome; Methionine; Mice, Inb | 2014 |
Maternal taurine supplementation attenuates maternal fructose-induced metabolic and inflammatory dysregulation and partially reverses adverse metabolic programming in offspring.
Topics: Animals; Cytokines; Dietary Supplements; Fatty Acid Synthases; Female; Fetal Development; Fructose; | 2015 |
Preventive effects of taurine on development of hepatic steatosis induced by a high-fat/cholesterol dietary habit.
Topics: Animals; Cholesterol, Dietary; Cricetinae; Dietary Fats; Disease Models, Animal; Fatty Liver; Gene E | 2011 |
A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease.
Topics: Adult; Animals; Biomarkers; Blood Glucose; Diet; Fatty Liver; Female; Glutamic Acid; Humans; Lactic | 2011 |
Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease.
Topics: Animals; Cell Death; Cell Line, Tumor; Chemical and Drug Induced Liver Injury; Diet; Endoplasmic Ret | 2011 |